Design Therapeutics, Inc. DSGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $14.38M+7.1% | $13.43M-8.0% | $14.59M-7.3% | $15.74M+2.3% | $15.38M+26.5% | ||
| $5.33M+12.3% | $4.74M+0.5% | $4.72M-19.0% | $5.83M+15.7% | $5.04M+11.1% | ||
| $19.71M+8.5% | $18.17M-5.9% | $19.31M-10.5% | $21.57M+5.6% | $20.42M+22.3% | ||
| -$19.71M-8.5% | -$18.17M+5.9% | -$19.31M+10.5% | -$21.57M-5.6% | -$20.42M-22.3% | ||
| —— | —— | —— | —— | —— | ||
| -$17.64M-10.2% | -$16M+5.9% | -$17M+10.9% | -$19.08M-7.7% | -$17.72M-29.8% | ||
| -$0.29-7.4% | -$0.27+10.0% | -$0.30+11.8% | -$0.34-9.7% | -$0.31-29.2% | ||
| -$19.55M-8.5% | -$18.01M+6.0% | -$19.16M+10.6% | -$21.42M-5.7% | -$20.26M-22.4% | ||
| -$19.71M-8.5% | -$18.17M+5.9% | -$19.31M+10.5% | -$21.57M-5.6% | -$20.42M-22.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Design Therapeutics, Inc. profitable?
- Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
- What is Design Therapeutics, Inc.'s earnings per share?
- Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
- Where does Design Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.